The rapid rise of GLP-1 weight loss drugs such as semaglutide and tirzepatide has created two parallel markets. One market consists of ...

ATLANTA, GA—In a finding that sheds some light on just how semaglutide helps the heart, patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes see ...

Novo Nordisk's 7.2 mg Wegovy injectable aims to enhance chronic weight management in adults with obesity, using an expedited ...

A higher dose of semaglutide achieves a 19% loss in body weight and redefines the limits of obesity treatment.

The clinical benefits of semaglutide (Wegovy; Novo Nordisk) in patients with the obesity phenotype of heart failure with preserved ejection fraction (HFpEF) don’t appear to be influenced by left ...

The World Health Organization on Monday issued its first guideline on the use of GLP-1 therapies for obesity, conditionally ...

Today, Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of ...

ORLANDO, Fla. — Women with heart failure with preserved ejection fraction (HFpEF) and obesity, with or without diabetes, derive the same benefit from the glucagon-like peptide 1 receptor agonist ...

Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

Patients with obesity and heart failure with preserved ejection fraction (HFpEF) treated with semaglutide improved in symptoms, functional capacity, and biomarkers over 1 year independently of ...